Skip to main content

Table 2 Clinical characteristics of all patients

From: Altered profile of immune regulatory cells in the peripheral blood of lymphoma patients

  Hodgkin lymphoma N (%) High-grade B-cell lymphoma N (%) All lymphoma patients N (%) Healthy blood donors N (%)
Patients 19 24 43 15
Male 13 (68) 16 (67) 29 (67) 9 (75)
Female 6 (32) 8 (33) 14 (33) 3 (25)
Unknown     3
Age
 Mean (range) 47 (22–84) 64 (35–85) 57 (22–85) 44 (20–69)
 Relapse 1 (5) 1 (4)   
 RT only   2 (8)   
 R-CHOP   20 (83)   
 ABV/ABVD 14 (74)    
 BEACOPP 2 (10)    
 Other treatment 3 (16) 2(8)   
 PD 3 (16) 2 (8)   
 DWD 3 (16) 3 (12) 6 (14)  
 AWD 1 (5) 0 (0)   
 Median follow-up time 23 18 19.8  
 Mean follow-up time (range) 20 (1–40) 23 (3–52) 21 (1–52)  
 ADF 15 (79) 19 (79)   
Stage
 1A 2 (10.5) 9 (38)   
 1B 2 (10.5)   
 2A 4 (21) 2 (8)   
 2B 2 (10.5) 2 (8)   
 3A 3 (16) 5 (21)   
 3B 3 (16) 1 (4)   
 4A 2 (10.5) 1 (4)   
 4B 1 (5) 4 (17)   
 B-symptoms 8 (42) 8 (33) 16 (37)  
IPS
 0–1 4 (21)   
 2 7 (37)   
 3 7 (37)   
  > 4 1 (5)   
IPI
 0–1 12 (50)   
 2 5 (21)   
 3 4 (17)   
 4 3 (12)   
  1. Abbreviations: RT radiotherapy, R-CHOP rituximab, cyclophosphamide, doxorubicine, vincristine, prednisone, ABVD doxorubicine, bleomycin, vinblastine, dacarbazine, AVD doxorubicine, vinblastine, dacarbazine, BEACOPP bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone